Parley is a neurotech company restoring how the brain hears.

Our mission

We are approaching a billion people quietly losing the conversations that keep them mentally sharp. We exist to give that capacity back, and in doing so, to address one of the most overlooked drivers of cognitive decline.

Leadership

Samuel Budoff

PhD - CEO, Co-Founder

Sam holds a PhD in Neuroscience and master's degrees in Neuroengineering and Statistics. He has eight years of biotech startup experience, including founding BaconBio Inc. (where he led the team to a patent) and serving as the 14th employee at Modern Meadow. At Parley, Sam is the co-Investigator leading clinical trial NCT07304024 after preparing the IND, he leads commercial strategy, fundraising, and operations.

Achim Klug

PhD - CSO, Co-Founder

Achim is a Professor at the University of Colorado Anschutz Medical Campus, where he has run the Klug Lab since 2009. He holds a PhD in Neurobiology and Zoology and 30 years of research focused on the auditory brainstem. He previously founded PopNeuron LLC and led it to revenue. He holds three issued U.S. patents and one pending patent on LOOT, and is the developer of Parley's underlying treatment. Achim is the lead Investigator on clinical trial NCT07304024.

The university clinicians behind the trial

Yuri Agrawal

MD, MPH
Professor of Otolaryngology
University of Colorado

Enrique Alvarez

MD, PhD
Professor of Neurology
University of Colorado

Vinaya Manchaiah

AuD, PhD
Professor of Otolaryngology
University of Colorado

Kayla Howerton

AuD, PhD
Audiology Clinic Director
University of Northern Colorado

Our Partners

Parley's research has been supported by:

Are you losing conversations in noisy rooms?

Phase II volunteer enrollment is open at CU Anschutz Medical Campus.

Are you a Montana ENT or audiologist?

Be among the first clinics in the country to offer LOOT

The ScienceFor CliniciansAboutNewsContactPrivacy PolicyTerms and Conditions

Parley Neurotech's experimental therapy has not yet been reviewed by the FDA. It will soon be accessible in Montana under the soon to be implemented right to try law, state Senate Bill 5353. Informed and consenting adults may request this experimental treatment in Montana from their clinician prior to FDA review of efficacy claims. Safety of the small molecule component of Parley Neurotech's combination therapy, clemastine fumarate at a lower dosage, has been approved by the FDA since 1977.